(Stroke. 2000;31:936.)
© 2000 American Heart Association, Inc.
Original Contributions |
C242T Polymorphism of NADPH Oxidase p22 PHOX Gene and Ischemic Cerebrovascular Disease in the Japanese Population
From the Departments of Neurology (D.I., N.T., Y.F.), Laboratory Medicine (M.M., K.W.), and Hematology (M.M.) and the Health Center (T.Y., I.S.), School of Medicine, Keio University, Tokyo, Japan.
Correspondence to Daisuke Ito, MD, Department of Neurology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Background and Purpose—Superoxide has been implicated in the pathogenesis of ischemic stroke and atherosclerosis. NADPH oxidase, a major source of superoxide generation in neutrophils and the vascular system, plays a critical role in ischemic injury and atherogenesis. Recently, an association between the C242T polymorphism of p22 PHOX, an essential component of NADPH oxidase, and coronary artery disease (CAD) has been reported in several studies. To investigate the relationship between the C242T polymorphism of p22 PHOX and ischemic cerebrovascular disease (CVD), we conducted a case-control study.
Methods—We recruited 226 CVD patients (atherothrombotic infarction, lacunar infarction, and transient ischemic attack) and 301 control subjects and analyzed C242T polymorphism of p22 PHOX by detection of restriction fragment length polymorphism.
Results—The TC+TT genotype frequencies in the CVD group
and control group were 21.7% and 13.3%, respectively, and the
prevalence of the TC+TT genotype was significantly higher in
the CVD patients (
2=6.477, P=0.01, OR
1.81, 95% CI 1.15 to 2.86). Analysis by CVD subtypes showed
that the OR for the TC+TT genotype was higher in the CVD
patients with atherothrombotic infarction than in those with lacunar
infarction and transient ischemic attack.
Conclusions—The C242T polymorphism of the NADPH oxidase p22 PHOX gene is a novel pathogenetic risk factor for CVD.
Key Words: cerebrovascular disorders • oxygen radical • polymorphism (genetics) • risk factors • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  M. Arca, B. Conti, A. Montali, P. Pignatelli, F. Campagna, F. Barilla, G. Tanzilli, R. Verna, A. Vestri, C. Gaudio, et al. C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 752 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bedard and K.-H. Krause The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology Physiol Rev, January 1, 2007; 87(1): 245 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Leopold and J. Loscalzo Oxidative Enzymopathies and Vascular Disease Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1332 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ago, T. Kitazono, J. Kuroda, Y. Kumai, M. Kamouchi, H. Ooboshi, M. Wakisaka, T. Kawahara, K. Rokutan, S. Ibayashi, et al. NAD(P)H Oxidases in Rat Basilar Arterial Endothelial Cells Stroke, May 1, 2005; 36(5): 1040 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsunaga-Irie, T. Maruyama, Y. Yamamoto, Y. Motohashi, H. Hirose, A. Shimada, M. Murata, and T. Saruta Relation Between Development of Nephropathy and the p22phox C242T and Receptor for Advanced Glycation End Product G1704T Gene Polymorphisms in Type 2 Diabetic Patients Diabetes Care, February 1, 2004; 27(2): 303 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
T. M. Paravicini, S. Chrissobolis, G. R. Drummond, and C. G. Sobey Increased NADPH-Oxidase Activity and Nox4 Expression During Chronic Hypertension Is Associated With Enhanced Cerebral Vasodilatation to NADPH In Vivo Stroke, February 1, 2004; 35(2): 584 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Hodgkinson, B. A. Millward, and A. G. Demaine Association of the p22phox Component of NAD(P)H Oxidase With Susceptibility to Diabetic Nephropathy in Patients With Type 1 Diabetes Diabetes Care, November 1, 2003; 26(11): 3111 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hayaishi-Okano, Y. Yamasaki, Y. Kajimoto, K.'y. Sakamoto, K. Ohtoshi, N. Katakami, D. Kawamori, T. Miyatsuka, M. Hatazaki, Y. Hazama, et al. Association of NAD(P)H Oxidase p22 phox Gene Variation With Advanced Carotid Atherosclerosis in Japanese Type 2 Diabetes Diabetes Care, February 1, 2003; 26(2): 458 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Meschia Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research Stroke, December 1, 2002; 33(12): 2770 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Van Heerebeek, C Meischl, W Stooker, C J L M Meijer, H W M Niessen, and D Roos NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J. Clin. Pathol., August 1, 2002; 55(8): 561 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Ito, N Tanahashi, M Murata, H Sato, I Saito, K Watanabe, and Y Fukuuchi Notch3 gene polymorphism and ischaemic cerebrovascular disease J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 382 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Whitehead and G. A. FitzGerald Twenty-First Century Phox: Not Yet Ready for Widespread Screening Circulation, January 2, 2001; 103(1): 7 - 9. [Full Text] [PDF]
|
|
|
|
|
|
D. Ito, M. Murata, N. Tanahashi, H. Sato, A. Sonoda, I. Saito, K. Watanabe, and Y. Fukuuchi Polymorphism in the Promoter of Lipopolysaccharide Receptor CD14 and Ischemic Cerebrovascular Disease Stroke, November 1, 2000; 31(11): 2661 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Guzik, N. E. J. West, E. Black, D. McDonald, C. Ratnatunga, R. Pillai, and K. M. Channon Functional Effect of the C242T Polymorphism in the NAD(P)H Oxidase p22phox Gene on Vascular Superoxide Production in Atherosclerosis Circulation, October 10, 2000; 102(15): 1744 - 1747. [Abstract] [Full Text] [PDF]
|
|